Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinte.1964.00280110138025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case.].
Recenti Prog Med
March 2025
SC Ematologia, Aou Città della Salute e della Scienza di Torino.
Introduction: Relapsed or refractory (R/R) mantle cell lymphoma (MCL) represent a setting at unfavourable prognosis. Chimeric antigen receptor T-cells (CAR-T) are recently introduced in clinical practice as a new therapeutic option for this setting.
Clinical Case: 61-year-old man with MCL pleomorphic variant, TP53 mutated with high risk MIPI-c early relapsed after frontline immunochemotherapy and ibrutinib.
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.
Front Immunol
March 2025
Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B cell non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy. Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse.
View Article and Find Full Text PDFEmerging cell therapies in the vasculitis field.
Rheumatology (Oxford)
March 2025
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
ANCA vasculitis is a systemic autoimmune small-vessel vasculitis characterized by autoantibodies targeting either MPO or PR3. While patients with ANCA vasculitis are successfully treated with broad-spectrum immunosuppression, these treatments often leave patients vulnerable to infections. Research in the field has made positive gains in regards to understanding autoantigen specificity and immune cell subset involvement in disease pathogenesis, relapse and remission.
View Article and Find Full Text PDFBiologic therapies for the treatment of large vessel vasculitis: A systematic review and meta-analysis.
PLoS One
March 2025
Department of Cardiovascular Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Objective: To summarize the existing evidence from double-blind randomized controlled trials (RCTs) and cohort studies regarding the effects of biologic agents for the treatment of large vessel vasculitis (LVV).
Methods: A systematic review and meta-analysis was conducted using MEDLINE, Embase, Cochrane Central Registry of Controlled Trials, and ClinicalTrials.gov covering the period from database inception to May 3rd, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!